Results 61 to 70 of about 72,871 (224)

Unintended Consequences of Life‐Saving Pharmaceutical Innovations: How HAART Led to the Resurgence of Syphilis

Health Economics, EarlyView.
ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti, Scott Cunningham, Nir Eilam   +2 more
wiley   +1 more source

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection [PDF]

, 2003
Although the pathogenesis of human immunodeficiency virus (HIV) infection and the general virologic and immunologic principles underlying the use of antiretroviral therapy are similar for all HIV-infected persons, there are unique considerations needed ...
Antiretroviral Therapy and Medical Management of HIV-Infected Children, ATMMHC, Health Resources and Services Administration, HRSA, National Institutes of Health, NIH, National Pediatric and Family HIV Resource Center, NPHRC   +3 more
core  

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Esmailzadeh, Negin L, Fong, Tiffany M, Grotts, Jonathan, Han, Steven-Huy B, Jimenez, Melissa A, Kachadoorian, Caterina A, Kang, Susan, Mai, Michelle H, Ramirez, Samantha D, Rheem, Justin, Saab, Sammy   +15 more
core   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]

, 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N, Bhattacharya, Debika, Dixit, Ram, Dixit, Vivek, Dong, Tien S, Han, Steven B, Jackson, Samuel, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +9 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. [PDF]

, 2015
Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding ...
D:A:D study group, ., ESPRIT study group, ., Fux, CA, INSIGHT study group, ., Johnson, MA, Kirk, O, Law, M, Lundgren, JD, Mocroft, A, Moranne, O, Morlat, P, Neuhaus, J, Reiss, P, Ross, M, Royal Free Hospital Clinic Cohort, ., Ryom, L, SMART study group, ., Smith, C, Wentworth, D   +18 more
core  

Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis [PDF]

, 2017
Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV ...
2LADY Study Group, Alexandra Calmy, Anne Derache, ANRS 12249 TasP Study Group, Collins Iwuji, Dami Collier, DART Virology Group and Trial Team, Deenan Pillay, EARNEST Trial Team, Francois Dabis, National Department of Health, National Department of Health, Nonhlanhla Okesola, PharmAccess African Studies to Evaluate Resistance (PASER), PharmAccess African Studies to Evaluate Resistance (PASER), Ravindra K. Gupta, SECOND-LINE, SECOND-LINE Study Group, Southern African Treatment and Resistance Network, TenoRes Study Group, Tulio de Oliveira, World Health Organization, World Health Organization   +22 more
core   +3 more sources